Sprint Bioscience AB (SPRINT.ST) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-585.4%

-SEK 16.65

vs SEK 3.43 price

Levered DCF

-SEK 53.15

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

16.98

Safe zone

Rating

B+

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	1.48×	-6×	-271.43×	-0.38×	-6.47×	-3.22×	-7.57×	-10.91×
P/B	1.14×	11.75×	4.3×	0.81×	2.32×	16.28×	15.61×	6.52×
P/S	0.81×	1.66×	2.36×	275.58×	4.66×	8.81×	5.13×	13.55×
EV / EBITDA	0.1×	-4.84×	175.36×	0.11×	-3.79×	-3.46×	-8.35×	-7.74×
Gross margin	58.2%	56.8%	82.8%	-73384.3%	70.3%	38.1%	75.6%	95.8%
Operating margin	58.2%	-30.0%	-1.7%	-73384.3%	-72.5%	-223.1%	-60.9%	-123.0%
Net margin	54.9%	-27.8%	-0.9%	-72494.0%	-72.2%	-273.8%	-67.8%	-123.9%
Current ratio	7.6×	1.14×	1.67×	3.78×	8.75×	1.33×	2.11×	0.83×
Debt / equity	0×	0×	0×	0×	0×	1.09×	0×	0.32×
Interest coverage	15.68×	-491.7×	0×	0×	-94.67×	-10.95×	-16.9×	-161.01×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	77.0%	-197.1%	-1.6%	-213.5%	-36.0%	-505.6%	-206.4%	-59.7%
Return on invested capital	81.7%	-212.1%	-3.0%	-216.1%	-36.1%	-196.8%	-185.4%	-44.8%
Return on assets	67.1%	-43.5%	-0.7%	-160.8%	-32.0%	-138.4%	-118.2%	-37.5%
Free cash flow yield	61.3%	-22.6%	17.1%	-258.2%	-26.2%	-21.7%	-16.3%	-12.4%
Earnings yield	67.4%	-16.8%	-0.4%	-263.1%	-15.5%	-31.1%	-13.2%	-9.1%
Enterprise value	SEK 9.4M	SEK 83.9M	SEK 69.4M	-SEK 6.6M	SEK 92.9M	SEK 131.8M	SEK 163.5M	SEK 240.3M
Net debt / EBITDA	-1.29×	1.45×	-126.1×	0.49×	2.88×	0.45×	0.43×	0.09×
Cash conversion cycle (days)	-10	-2	-234	14,824	-71	9	-58	-2,410